IMV, Inc., a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, announced a first patient dosed in the VITALIZE Phase IIB clinical trial.
[IMV Inc.]
7992332
{7992332:nan}
apa
50
1
170855
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
